Launch of Abingdon Simply Test e-commerce website

RNS Number : 2113T

Abingdon Health PLC

21 July 2022

 

Abingdon Health plc

("Abingdon" or "the Company")

Launch of Abingdon Simply Test e-commerce website

York, U.K. 21 July 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces the launch of its new B2C e-commerce website, abingdonsimplytest.com .

The Abingdon Simply Test website will provide UK and international customers with Abingdon Simply Test and Abingdon-assured third-party branded self-tests. All products will be regulatory approved and manufactured under international quality management systems.

The e-commerce site has launched with a range of tests in areas such as fertility, health and well-being and infectious disease. It is Abingdon's intention to broaden the range of available tests, with a focus on self-testing.

The Abingdon Simply Test website will provide consumers with simple, jargon-free information to enable them to make considered purchasing decisions. All tests on the abingdonsimplytest.com site will also have undergone Abingdon's 10-point evaluation covering quality, regulatory and usability requirements to provide customers with greater assurance on the quality of these tests.

Self-testing is a major growth area within the global diagnostic market and in its recent report, Future Market Insights forecast the global market for self-testing kits will be worth US $11bn by 2030¹. Lateral flow testing has seen a significant increase in profile and familiarity following the rapid expansion of COVID-19 lateral flow self-testing during the pandemic. The increased awareness amongst the general public of lateral flow testing coupled with its benefits such as low cost and ease-of-use means that LFT testing will play a major role in the democratisation of testing and the empowerment of individuals to manage their own health.

Chris Yates, CEO of Abingdon Health plc, commented: "The healthcare landscape is changing and the increase in lateral flow testing during the COVID-19 pandemic has served as a catalyst for a paradigm shift in moving diagnostic testing out of the laboratory and into the home. Consumers are increasingly taking a more, proactive approach to managing their health and wellbeing and this is leading to the growth of the self-health and self-testing market. The launch of our Abingdon Simply Test site will provide focal point for consumers wishing to purchase lateral flow self-tests and will support people in taking an empowered role in managing their own health and wellbeing."

¹ https://www.futuremarketinsights.com/reports/self-testing-market

Enquiries:

Abingdon Health plc			www.abingdonhealth.com/investors/
Chris Yates,  Chief Executive Officer			Via Walbrook PR
Melanie Ross , Chief Financial Officer
Dr Chris Hand,  Non-Executive Chairman
Singer Capital Markets (Sole Broker and Nominated Adviser)			Tel: [phone]
Peter Steel, Alex Bond, Sam Butcher (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited		Tel: [phone] or  [e-mail]
Paul McManus / Phillip Marriage	Mob: [phone]
Alice Woodings	Mob: [phone]

 

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality lateral flow rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx^®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

 

END

 

 

NRAPPUPCMUPPGMU